About the Defeat GBM Research Collaborative

The Defeat GBM Research Collaborative, a subsidiary of the National Brain Tumor Society, is a multifaceted and concentrated effort, which aims to double the five-year survival rate of GBM patients – in just five years.

To achieve this goal, the Defeat GBM Research Collaborative will connect leading brain tumor researchers from top cancer institutions across the globe to create a tightly-focused and outcomes-driven effort. Through research collaboration, multiple synergistic projects will be combined and driven by investigator teams with proven track records of results to accelerate the pace of discovery and improve patient survival. By design, the four (4) individual projects within the overall Defeat GBM initiative will provide better and strategic data sharing opportunities to inform the overall effort, and advance potential therapies down the drug discovery pipeline more quickly.

A team of senior brain cancer experts acting as the Strategic Scientific Advisory Council (SSAC) will oversee the Defeat GBM Research Collaborative to ensure goal attainment and overall success. This esteemed group of research leaders will partner with Defeat GBM’s Managing Director, Carrie Treadwell (National Brain Tumor Society, Senior Director of Research) and its Scientific Director, Dr. W.K. Alfred Yung, Margaret and Ben Love Chair of Clinical Cancer Care, and Professor of Neuro-Oncology and Cancer Biology at The University of Texas MD Anderson Cancer Center to direct the overall research initiative.

“…doctors and researchers involved in this Initiative all have the same level of understanding and enthusiasm for finding a solution for this disease. And we all share the same sense of urgency to do better for patients.” -Dr. W.K. Alfred Yung